RXRX — Recursion Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.55bn
- $826.21m
- $74.68m
Annual cashflow statement for Recursion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -186 | -239 | -328 | -464 | -645 |
| Depreciation | |||||
| Non-Cash Items | 19.8 | 39.3 | 66.1 | 106 | 176 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.306 | 105 | -50.3 | -38 | 13.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -159 | -83.5 | -288 | -359 | -372 |
| Capital Expenditures | -39.8 | -37.1 | -12 | -13.7 | -6.47 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -232 | 230 | 1.73 | 274 | -10.4 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -272 | 193 | -10.2 | 260 | -16.9 |
| Financing Cash Flow Items | 0 | — | — | — | -3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 459 | 154 | 140 | 304 | 522 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28.2 | 264 | -158 | 202 | 151 |